1 recruiting, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow KP 1339: new trials by email Literature Review of KP 1339 trials Research Report on KP 1339
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas BOLD-100, Doxorubicin 75 mg/m^2 - Sarcoma, Soft-tissue, Sarcoma | Phase 1 | Withdrawn | University Health Network, Toronto | 2026-03-30 | 2026-11-13 | |
| BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI) - Colorectal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Bold Therapeutics, Inc. | 220 | 2020-08-28 | 2026-10-28 |
Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Stomach Neoplasms (1)
Bold Therapeutics, Inc. (1) · University Health Network, Toronto (1)
Canada (2) · Germany (1) · Ireland (1) · Italy (1) · South Korea (1) · Spain (1) · United Kingdom (1) · United States (1)